864068-97-3 Usage
Uses
Used in Organic Synthesis:
(1-METHYL-3-PHENYL-1H-PYRAZOL-5-YL)METHANOL is used as a key intermediate in organic synthesis for the development of new chemical entities. Its unique structure allows for versatile reactions and modifications, facilitating the creation of a range of compounds with potential applications in various fields.
Used in Pharmaceutical Research:
In the pharmaceutical industry, (1-METHYL-3-PHENYL-1H-PYRAZOL-5-YL)METHANOL is utilized as a starting material or a building block in the synthesis of drugs and biologically active molecules. Its pyrazole core is a common structural motif found in many pharmaceuticals, making it a valuable component in drug discovery and development.
Used in Medicinal Chemistry:
(1-METHYL-3-PHENYL-1H-PYRAZOL-5-YL)METHANOL may possess its own medicinal properties, warranting its use in medicinal chemistry for further exploration and understanding of its potential therapeutic applications. (1-METHYL-3-PHENYL-1H-PYRAZOL-5-YL)METHANOL's structure could be optimized to enhance its pharmacological activity and selectivity, leading to the development of new therapeutic agents.
Used in Chemical Research:
As a derivative of pyrazole, (1-METHYL-3-PHENYL-1H-PYRAZOL-5-YL)METHANOL is also used in chemical research to study the properties and reactivity of pyrazole-containing compounds. This research can provide insights into the design and synthesis of novel pyrazole-based compounds with improved properties and applications.
Check Digit Verification of cas no
The CAS Registry Mumber 864068-97-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,4,0,6 and 8 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 864068-97:
(8*8)+(7*6)+(6*4)+(5*0)+(4*6)+(3*8)+(2*9)+(1*7)=203
203 % 10 = 3
So 864068-97-3 is a valid CAS Registry Number.
InChI:InChI=1/C11H12N2O/c1-13-10(8-14)7-11(12-13)9-5-3-2-4-6-9/h2-7,14H,8H2,1H3
864068-97-3Relevant academic research and scientific papers
Lead Optimization Generates CYP11B1 Inhibitors of Pyridylmethyl Isoxazole Type with Improved Pharmacological Profile for the Treatment of Cushing's Disease
Emmerich, Juliette,Van Koppen, Chris J.,Burkhart, Jens L.,Hu, Qingzhong,Siebenbürger, Lorenz,Boerger, Carsten,Scheuer, Claudia,Laschke, Matthias W.,Menger, Michael D.,Hartmann, Rolf W.
supporting information, p. 5086 - 5098 (2017/06/28)
Cushing's disease, characterized by elevated plasma cortisol levels, can be controlled by inhibition of 11β-hydroxylase (CYP11B1). The previously identified selective and potent CYP11B1 inhibitor 5-((5-methylpyridin-3-yl)methyl)-2-phenylpyridine Ref 7 (IC50= 2 nM) exhibited promutagenic potential as well as very low oral bioavailability in rats (F = 2%) and was therefore modified to overcome these drawbacks. Successful lead optimization resulted in similarly potent and selective 5-((5-methoxypyridin-3-yl)methyl)-3-phenylisoxazole 25 (IC50 = 2 nM, 14-fold selectivity over CYP11B2), exhibiting a superior pharmacological profile with no mutagenic potential. Furthermore, compound 25 inhibited rat CYP11B1 (IC50 = 2 μM) and showed a high oral bioavailability (F = 50%) and sufficient plasma concentrations in rats, providing an excellent starting point for a proof-of-principle study.
Inhibitors of viral replication, their process of preparation and their therapeutical uses
-
Page/Page column, (2014/05/06)
The present invention relates to compounds of formula (I), their use in the treatment or the prevention of viral disorders, including HIV. wherein R1, R2, R3 and R4 are as included in the claims.
